Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCS-01
- Development stage
- Phase 1
- Lead developer
- RepliCel Life Sciences
- Modality
- Cell Therapies
- Administration
- Intradermal
01
Overview
RCS-01 is an autologous cell therapy developed by RepliCel Life Sciences for skin rejuvenation, specifically targeting aging or sun-damaged skin. The product consists of non-bulbar dermal sheath (NBDS) cells (fibroblasts) harvested from a patient's own hair follicles. These cells are isolated, expanded ex vivo, and then re-injected into the dermis to stimulate collagen production and restore skin structure. RepliCel has licensed the rights for Greater China to YOFOTO (China) Health, which is co-developing the product and conducting Phase 2 clinical trials in that region. The therapy is intended to be delivered using the proprietary RCI-02 dermal injector.
- Other names
- RCS-01RCS01RCS 01
Beyond the preview
Go deeper on RCS-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RCS-01.